Effect of Ketotifen and Cyproheptadine on Appetite and Weight Changes in Mice Change of appetite and weight by antihistamins
Iranian Journal of Pharmaceutical Sciences,
دوره 2 شماره 3 (2006),
1 تیر 2006
,
صفحه 123-128
https://doi.org/10.22037/ijps.v2.39630
چکیده
Ketotifen is a potent, safe and long acting antihistamine that is effective in treatment of asthma and its use is believed to causes weight gain and drowsiness.
Cyproheptadine, an antihistamine, has anticholinergic and antiserotonergic effects, and causes increases of the appetite and weight gain. In this study the effects of different doses of ketotifen and/or cyproheptadine on the appetite and weight changes in mice is evaluated. Sixty four male mice were divided in 8 groups and received the following drug regimens for 45 days. Control group, normal saline (10 ml/kg, s.c.), three groups of cyproheptadine (5, 10, 20 mg/kg, s.c.), three groups of ketotifen (8, 16, 32 mg/kg, s.c.), and one group cyproheptadine (5 mg/kg, s.c.) combined with ketotifen (8 mg/kg, s.c.). Weight changes caused by above drug regimens were recorded every 2 days and average of food intake was recorded every day for 45 days. The results showed that the high dose of ketotifen (32 mg/kg, s.c.) increased weight, significantly, but its low dose (8 mg/kg, s.c.) decreased weight significantly. Cyproheptadine (5 mg/kg, s.c.) caused significant increase in weight gain and stimulated appetite, but its high dose of (20 mg/kg, s.c.), decreased the appetite and weight. Co-administration of cyproheptadine and ketotifen decreased the appetite, significantly. The results showed that different doses of cyproheptadine and ketotifen have different effects on the appetite and weight gain in mice, and possibly different mechanisms of action.
- Appetite
- Cyproheptadine
- Ketotifen
- Weight change
ارجاع به مقاله
مراجع
[2] Prelipcean MS, O'Neil PJ, Bell DS. Hyperinsulinemic hypoglycemia precipitated by weight loss. South Med J 2005; 98: 726-8.
[3] Crowley VE, Spiegelman BM. Obesity therapy: Altering the energy intake and expend iture balance sheet. Nat Rev Drug Disc 2002; 1: 276-81.
[4] Flier JS, Maratos-Flier E. Obesity. In: Kasper DL et al, (editors). Harrison's principles of internal medicine. 16nd ed. New York McGrawHill, 2005; pp. 422-9.
[5] Guyton AC, Hall JF. Medical physiology, 10th ed. Philadelphia: Saunders Company, 2000; pp. 755-7.
[6] McDaniel WW. Serotonin syndrome: Early management with cyproheptadine. Ann Pharmacother 2001; 35: 870-3.
[7] Herfindal ET, Gourley DR Textbook of therapeutics drug and disease management, 7th ed. New York: Lippincott Williams and Nilkins, 2000; pp. 1277-80.
[8] Ferriols LF, Tordera BM. Wasting syndrome in cancer patients: Pathophysiology, manifestations and drug therapy. Farm Hosp 2003; 27: 308-16.
[9] Schwartzer G, Bassler D, Mitra A, Duchame FM, Forster J. Ketotifen alone or as additional medication for longterm control of asthma and wheeze in children. Cochrane Database Syst Rew 2004; CD001384.
[10] Nevzorova VA, Prosekova EV, Gel'ster BI, Lukianov PA, Shestoskaia Iu V, Arzamastseva AI. Changes in biochemical inflammation markers in evaluation of the effectiveness of basic chemotherapy in bronchial asthma. Ter Arkh 2001; 73: 24-7.
[11] Ockenga J, Rohde F, Suttman U, Herbarth L, Ballmaier M, Schedel I. Ketotifen in HIV infected patients: Effects on bady weight and release of TNF-α . Eur Clin Pharmacol 1996; 50: 167-70.
[12] Katzung BG. Histamine, serotonin and the ergot alkaloids. In: Katzung BG, (editor). Basic and clinical pharmacology, 9th ed. New York: McGraw Hill, 2004: pp. 259-68.
[13] Martin UL, Romer D. The pharmacological properties of a new orally active antianaphylactic compound: Ketotifen a benzocyclo heptatiophen. Drug Res 1993; 28: 770-82.
[14] Kern PA, Sghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor α in human adipose tissue, regulation by obesity, weight loss and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-5.
[15] Grundfeld G, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. New Engl J Med 1992; 327: 329-37.
[16] Caps LP. Immunologic and therapeutic aspects of ketotifen. Allergy 1991; 11: 189-91.
[17] Joel F. Lehrer cyproheptadine's antiserotonin effects are responsible for its antimigraine activity headache. J Head Face Pain 2004; 44: 935.
[18] Xin HB, Zhang BH. Scavenging effects of cyproheptadine on oxygen free radicals. Yao Zue Xue Bao 1993; 28: 161-5.
[19] Homnick DN, Marks JH, Hare KL, Bonnema SK. Long-term trial of cyproheptadine as appetite stimulant in cystic fibrosis. Pediatr Pulmol 2005; 40: 251-6.
[20] Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induce weight loss. J Child Adolesc Psychopharmacol 2004; 14: 65- 73.
- چکیده مشاهده شده: 81 بار
- IJPS_Volume 2_Issue 3_Pages 123-128 (English) دانلود شده: 28 بار